GlassScriptPhysician profile
Calvin D Ebels
NPI 1306063532
$11,086.87
in general payments reported to CMS, 2019-2025
24 companies · $4,333 in 2025
The $4,333 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $439 · 2021: $863 · 2022: $1,283 · 2023: $1,280 · 2024: $1,931 · 2025: $4,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,677 · Travel and Lodging: $823 · Entertainment: $44.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,676.89 |
| Travel and Lodging | $823.11 |
| Entertainment | $44.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,211.98 | 2020-2025 | |
| Alcon Vision LLC | $1,956.99 | 2019-2025 | Hydrus Microstent, Total30, Rocklatan |
| Coopervision INC. | $1,505.11 | 2019-2025 | Myday Contact Lens |
| Carl Zeiss Meditec USA, INC. | $1,070.13 | 2021-2024 | Forum, Cirrus Hd-Oct |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $738.04 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $695.62 | 2022-2025 | Xiidra, Miebo, Infuse |
| Sight Sciences, INC. | $569.55 | 2022-2025 | Tearcare System |
| Abbvie INC. | $405.17 | 2022-2024 | Vuity, Lumigan |
| Tarsus Pharmaceuticals, INC. | $358.35 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $292.33 | 2021-2025 | |
| Nova Eye, INC. | $275.01 | 2025 | |
| Carl Zeiss Meditec, INC. | $174.12 | 2019 | |
| Allergan, INC. | $148.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $137.12 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2025 | Syfovre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $92.81 | 2019 | |
| Kala Pharmaceuticals, INC. | $60.95 | 2021 | |
| Lkc Technologies, INC. | $56.59 | 2025 | |
| Oyster Point Pharma, INC. | $55.07 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Optos, INC. | $44.79 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $41.96 | 2021 | |
| Shire North American Group INC | $24.56 | 2019 | |
| Dompe US, INC. | $24.21 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $23.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Ebels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.